权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Identification of novel therapeutic combinations for NF2 schwannomas

鉴定 NF2 神经鞘瘤的新型治疗组合

基本信息

批准号：
10564452
负责人：
Steven P Angus
金额：
$ 46.33万
依托单位：
INDIANA UNIV-PURDUE UNIV AT INDIANAPOLIS
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-02-15 至 2028-01-31
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10564452
关键词：
Ablation Acoustic Neuroma Affect Affinity Chromatography Alleles Benign Bilateral Biochemical Brain Stem Bromodomains and extra-terminal domain inhibitor CRISPR screen CRISPR/Cas technology Cell Culture Techniques Cells Cessation of life Characteristics Clinic Clinical Research Clinical Trials Data Dependence Development Drug Combinations Drug Synergism Drug Targeting Evaluation Excision Exhibits FDA approved Facial Muscles Focal Adhesion Kinase 1 Generations Genetic Genetically Engineered Mouse Genomic approach Goals Growth Histology Human In Vitro Incidence Individual Investigational Therapies Kinetics Knock-out Laboratories Link Logistics Loss of Heterozygosity LoxP-flanked allele MAP Kinase Gene MEKs Malignant Neoplasms Mass Spectrum Analysis Mediating Modeling Molecular Morbidity - disease rate Motor Mus Muscle Weakness Mutation Neurilemmoma Neurofibromatosis 2 Neurofibromin 2 Neurologic Operative Surgical Procedures PTK2 gene Pathologic Pathway interactions Patients Persons Pharmaceutical Preparations Pharmacologic Substance Phase Phase I/II Clinical Trial Phosphotransferases Predisposition Proteins Rare Diseases Receptor Protein-Tyrosine Kinases Research Personnel Resistance Role Schwann Cells Signal Transduction Spinal Syndrome Testing Therapeutic Toxic effect Translations Tumor Suppressor Genes Tumor Tissue Tyrosine Kinase Inhibitor Vertebral column Vertigo Work anaplastic lymphoma kinase autosome bilateral vestibular Schwannoma cancer predisposition chemotherapy chronic neuropathic pain chronic pain combinatorial crizotinib deafness early phase clinical trial effective therapy experimental study hearing impairment improved in vivo inhibitor innovation insight kinase inhibitor nervous system disorder next generation novel strategies novel therapeutics pharmacologic pre-clinical preclinical efficacy preclinical study precursor cell progressive hearing loss rare cancer response screening single-cell RNA sequencing small molecule success synergism targeted treatment transcriptome translational potential tumor tumor growth tumor progression tumorigenesis tumorigenic

项目摘要

PROJECT SUMMARY / ABSTRACT Neurofibromatosis type 2 (NF2) is an autosomal dominant cancer predisposition syndrome characterized by germline haploinsufficiency at the NF2 locus, which encodes Merlin. NF2 patients characteristically develop bilateral vestibular schwannomas (VS) and spinal schwannomas as a result of loss of heterozygosity of NF2 in Schwann cells or Schwann cell precursors. Although these tumors are largely benign, their growth can result in significant neurological deficiencies including, but not limited to, deafness, vertigo, facial muscle weakness, chronic neuropathic pain, and death. Because of the extensive morbidity associated with surgical removal of these tumors, there is an urgent need to develop pharmaceutical approaches to halt or reverse the progression of tumor growth in these patients. To date, no long-term effective therapies exist for these highly debilitating tumors. Given the challenging clinical trial logistics in a rare tumor predisposition syndrome such as NF2, it is critical to establish a strategy linking preclinical and clinical studies for rapid translational innovation and efficiency. We have developed genetically engineered mouse models (GEMMs) of NF2 that accurately recapitulate tumor growth kinetics and histopathologic characteristics observed in NF2 patients—VS and paraspinal schwannomas with 100% incidence, combined with progressive hearing loss that occurs with VS formation. Using the Nf2 GEMM, we determined that the FDA approved multi-receptor tyrosine kinase (RTK) inhibitor brigatinib reduced schwannoma tumor size and tumor number. Brigatinib is approved to treat cancer driven by another kinase, anaplastic lymphoma kinase (ALK) and two ALK inhibitors, crizotinib and brigatinib, have both shown preclinical efficacy against NF2-associated schwannomas and are under evaluation in active clinical trials. While our findings suggest a role for FAK1 in modulating tumor progression, our understanding of the role of FAK1 as a single target for NF2 tumors or in combination with other drug targets is incomplete. We propose to build on our recent preclinical work by genetic ablation of FAK1 (Ptk2) in murine (Nf2) and human (NF2) deficient Schwann cells to establish the role of FAK1 (Ptk2) in promoting the genesis of Nf2 deficient schwannomas and associated morbidities (Aim 1). Drug synergy screening with post-IND FAK inhibitors alone and in combination with RAF, MEK, and BET bromodomain inhibitors to target cooperating Merlin-regulated pathways (Aim 2), and unbiased CRISPR-Cas9 kinome knockout screening in murine and human cells to identify FAK1-dependent kinase vulnerabilities that can be exploited therapeutically, alone or in combination (Aim 3). Our overarching goal with experiments in this application is to identify drugs or drug combinations that could expediently proceed to phase I/II clinical trials for patients with this debilitating neurological disease.

项目摘要/摘要